



NICE: Medicines Concordance Guideline  
Guideline Development Group (GDG) Meeting Minutes

**Date and Time:** 2<sup>nd</sup> July 2008

**Place:** Conwy Room, National Institute for Health and Clinical Excellence

**Present:** **GDG members**  
Chair: Dr Henry Smithson (HS)

Dr Mahendra Patel, Dr Wendy Clyne, Mr Shaun Johnson, Mr Stephen Hemingway, Dr John Benson, Prof Robert Horne, Mrs Alison Bowser, Mr Jim Blair, Prof Peter Crome, Dr Jonathan Steel, Dr Sean Kelly.

**In attendance:**

<b>NCC Staff:</b>	Dr. Norma O’Flynn Ms Vanessa Nunes Ms Julie Neilson Ms Stefanie Kuntze	
<b>Apologies:</b>		
	Ms Sarah Willett, NICE Mrs Bunis Packham Prof Peter Haddad.	

DOI

**Rob Horne**

.June 08 Grand Round at Merck Outcomes USA-paid  
Talk on adherence in HIV for BMS on 4th July 2008-  
paid

Consultancy on adherence research to shire  
pharmaceuticals

Consultancy on adherence to GSK

Consultancy on adherence in IBD to Procter and  
Gamble

Awarded unrestricted educational grant to University of  
London to conduct research into patient perspectives  
and adherence to phosphate reduction treatments in  
renal disease for Shire pharmaceuticals £100k 2008-  
2009

**Peter Haddad**

Since joining the GDG in Feb '07 I have attended  
several medical conferences (all on a range of  
psychiatric subjects and organized by independent  
bodies) with my associated expenses being paid by  
various drug companies.

A hospital administrator was in contact with myself to  
inform that on reviewing the research contract some  
money from the above study was actually payable to  
my research fund at the Trust and this payment has  
subsequently been made into my Trust research fund. I  
have not taken any private payment. The sum of  
money paid into my Trust research fund was less than  
£3000

I hold the view and have expressed it in writing, that  
long acting antipsychotic injections may improve  
adherence, compared to oral antipsychotics, in some  
patients with schizophrenia

Payment from my research fund for work as a Co-  
Investigator in an on-going investigator-led study of  
quetiapine as an augmenting agent in treatment-  
resistant depression. The grant for this study came from  
Astra-Zeneca.

**Henry Smithson**

Funding to attend ECE conference in Berlin by EISAI

TIME	TOPIC	TO LEAD
9.30	<i>Coffee available</i>	All
10.00	<p>Dr Henry Smithson gave a brief overview of:</p> <ul style="list-style-type: none"> <li>• Introductions and apologies</li> <li>• Agenda</li> <li>• Declarations of Interest</li> <li>• Review of minutes from last meeting for website</li> </ul>	Henry Smithson Norma O'Flynn
10.15	<p>Ms Vanessa Nunes and Ms Julie Neilson gave an overview of the evidence, mainly focusing on:</p> <ul style="list-style-type: none"> <li>• Revisions made to the evidence review on consultation length</li> <li>• Evidence review on self-report as a measure of adherence to prescribed medication</li> </ul>	Vanessa Nunes Julie Neilson
10.45	<p>Dr Henry Smithson and Dr Norma O'Flynn led the discussion on the agreement of recommendation developed so far</p> <ul style="list-style-type: none"> <li>• Decisions in the consultation</li> <li>• Assessing adherence</li> <li>• Interventions to increase adherence</li> <li>• Medication review</li> </ul>	Henry Smithson
13.00	<b>Lunch</b>	
13.30	Dr Norma O'Flynn continued to lead discussion on the agreement of recommendations developed so far	Norma O'Flynn
14..30	Dr Norma O'Flynn Let on the discussion to agree Key priorities for implementation (KPIs) and research recommendations	Norma O'Flynn
15.30	<p>Dr Henry Smithson Gave an overview of next steps, meeting dates, and any other business</p> <ul style="list-style-type: none"> <li>- Implementation planning meeting on the 9<sup>th</sup> September- two more GDG members to attend</li> <li>- GDG members to look at specific chapters of the guideline</li> </ul>	Henry Smithson
16.00	<i>Close</i>	All

Summary of next steps, meeting dates, and any other business

Next meeting: 2<sup>nd</sup> July , NICE